Carfilzomib is a proteasome inhibitor that specifically binds to PSMB8 [35,40]; on the other hand, 5-FU is an inhibitor of DNA and RNA synthesis and a primary component of FLOT, a standard treatment regime for GC patients [29,42]. Here, PSMB8 is linked to gastric cancer.